| Title |
Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study
|
|---|---|
| Published in |
Journal of Neuro-Oncology, July 2016
|
| DOI | 10.1007/s11060-016-2202-1 |
| Pubmed ID | |
| Authors |
Magnus Sabel, Gudrun Fleischhack, Stephan Tippelt, Göran Gustafsson, François Doz, Rolf Kortmann, Maura Massimino, Aurora Navajas, Katja von Hoff, Stefan Rutkowski, Monika Warmuth-Metz, Steven C. Clifford, Torsten Pietsch, Barry Pizer, Birgitta Lannering, On behalf of the SIOP-E Brain Tumour Group |
| Abstract |
The HIT-SIOP-PNET4 randomised trial for standard risk medulloblastoma (MB) (2001-2006) included 338 patients and compared hyperfractionated and conventional radiotherapy. We here report the long-term outcome after a median follow up of 7.8 years, including detailed information on relapse and the treatment of relapse. Data were extracted from the HIT Group Relapsed MB database and by way of a specific case report form. The event-free and overall (OS) survival at 10 years were 76 ± 2 % and 78 ± 2 % respectively with no significant difference between the treatment arms. Seventy-two relapses and three second malignant neoplasms were reported. Thirteen relapses (18 %) were isolated local relapses in the posterior fossa (PF) and 59 (82 %) were craniospinal, metastatic relapses (isolated or multiple) with or without concurrent PF disease. Isolated PF relapse vs all other relapses occurred at mean/median of 38/35 and 28/26 months respectively (p = 0.24). Late relapse, i.e. >5 years from diagnosis, occurred in six patients (8 %). Relapse treatment consisted of combinations of surgery (25 %), focal radiotherapy (RT 22 %), high dose chemotherapy with stem cell rescue (HDSCR 21 %) and conventional chemotherapy (90 %). OS at 5 years after relapse was 6.0 ± 4 %. In multivariate analysis; isolated relapse in PF, and surgery were significantly associated with prolonged survival whereas RT and HDSCR were not. Survival after relapse was not related to biological factors and was very poor despite several patients receiving intensive treatments. Exploration of new drugs is warranted, preferably based on tumour biology from biopsy of the relapsed tumour. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 131 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| United States | 1 | <1% |
| France | 1 | <1% |
| Unknown | 128 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 18 | 14% |
| Student > Ph. D. Student | 16 | 12% |
| Student > Master | 14 | 11% |
| Researcher | 13 | 10% |
| Other | 13 | 10% |
| Other | 27 | 21% |
| Unknown | 30 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 59 | 45% |
| Biochemistry, Genetics and Molecular Biology | 8 | 6% |
| Agricultural and Biological Sciences | 6 | 5% |
| Neuroscience | 5 | 4% |
| Nursing and Health Professions | 3 | 2% |
| Other | 12 | 9% |
| Unknown | 38 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 January 2021.
All research outputs
#6,307,246
of 22,880,691 outputs
Outputs from Journal of Neuro-Oncology
#777
of 2,977 outputs
Outputs of similar age
#105,757
of 356,439 outputs
Outputs of similar age from Journal of Neuro-Oncology
#7
of 59 outputs
Altmetric has tracked 22,880,691 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 2,977 research outputs from this source. They receive a mean Attention Score of 4.2. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 356,439 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.